We sought to compare three modalities of measurements of the aortic annulus, transthoracic (TTE), transesophageal echocardiography (TEE), and multislice computed tomography (MSCT), and to evaluate their potential clinical impact on transcatheter aortic valve implantation (TAVI) strategy.
Results:
Correlations between methods were good but absolute difference between MSCT and TTE (1.22±1.3 mm) or TEE (1.52±1.1 mm) was significantly larger than the absolute difference between TTE and TEE (0.6±0.8 mm, p=0.03 and p<0.0001 respectively). As regard to TAVI strategy, agreement between TTE and TEE was good overall (Kappa 0.68) but the TAVI strategy would have been different in 8 patients (17%). Agreement between MSCT and TTE or TEE was only modest (Kappa 0.28 and 0.27) and a decision based on MSCT measurements would have modified the TAVI strategy in a large number of patients (40% and 42%). Implantation was performed in 34 patients (76%) based on TEE measurements and was successful in all but one patient who had a grade 3 aortic regurgitation.
Conclusions:
In this group of patients with AS referred for TAVI, measurements of the aortic annulus using TTE, TEE and MSCT were close but not identical and the method used has important potential clinical implications on TAVI strategy. In the absence of gold standard, a strategy based on TEE measurements provided good clinical results.
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Characteristics, management and one-year outcome of patients hospitalized for severe aortic stenosis in a contemporary era Jeannette Fares (1), Hélène Eltchaninoff (2), Mathieu Godin (2), Fabrice Bauer (2), Christophe Tron (2), Alain Cribier (2) (1) CHU de Rouen, Imagerie médicale et Cardiologie, Rouen, CHU de Rouen, Cardiologie, Rouen, France Purpose: We evaluate clinical characteristics, management and prognosis of patients (Pts) with severe aortic stenosis (AS) hospitalized in a university hospital offering all therapeutic options: AVR, balloon aortic valvuloplasty (BAV) and transcutaneous heart valve implantation (TAVI) using the Edwards Sapien bioprosthesis.
Methods:
We included 211 Pts with severe AS (EOA < 1 cm 2 and/or 0.6 cm 2 /m 2 ), hospitalised between July, 2006 and July, 2007 in our center. Clinical, echocardiographic and angiographic characteristics, logistic EuroSCORE and STS score were evaluated. A prospective clinical and echocardiographic follow-up was performed at 1-year.
Results: 211 Pts (79 ± 9 years; 53% female) were included in the study. 58% of Pts were > 80 years old. 65% of Pts were highly symptomatic (NYHA 3-4). After multidisciplinary evaluation, 92 (43.6%) patients were referred to surgical AVR, 20 (9.5%) to TAVI, 62 (29.4%) to BAV and 37 (17.5%) were maintained on medical treatment alone. Pts treated by AVR were younger (74+/-9 vs 84+/-5, p< .0001) and had less frequent history of myocardial infarction (p=0.003) or coronary artery bypass grafts (p=0.0002), less renal failure (p<0.001), less severe lung disease (p=0.009), and less demetia (p=0.0002) than the 3 other groups. Operative risk was lower in the AVR group as assessed by Euroscore (8% vs 25%, p< .0001) and STS score (4.4 vs 13.0%, p< .0001). At one year, survival was excellent in the AVR group (99%) with no procedural death. At the opposite, 51% of Pts treated medically died. BAV improved symptoms (24% in NYHA IV vs 58% at baseline) and survival was 66% at 1-year. Survival rate in the TAVI group was 79% with marked symptoms improvement (70% of Pts in NYHA 1-2 vs 1% at baseline).
Conclusions:
Patients with severe AS represent a very heterogeneous population. Surgical AVR remains the reference treatment with excellent results. However, TAVI is a promising alternative treatment in many Pts with heavy and multiple comorbidities.
